Newsfeed

Macitentan Significantly Reduces PAH-Related Hospitalization
In a new report entitled “Effect of Macitentan on Hospitalizations: Results From the SERAPHIN Trial,” researchers describe the benefits of a Macitentan 10 mg dose in reducing the risk for hospitalization in patients with symptomatic pulmonary arterial hypertension. The report was published in the journal of the American College of Cardiac Foundation (JACC) Heart Failure. Pulmonary arterial hypertension (PAH) is a progressive, life-threatening …
#PHAware – Boy Raises Awareness For PH And Rare Disease Day On February 28
Lucas Van Wormer, a thirteen-year-old voice actor with PH working at Cartoon Network, along with his father, partnered with a credit union to raise awareness for pulmonary hypertension. The entertainment industry’s First Entertainment Credit Union along with celebrities like Courteney Cox, Florence Henderson, Laura Dern and Jeffrey Hayzlett are fighting for the cause as well. On a typical day, Lucas Van Wormer does voice overs at Cartoon Netwo…
Auburn's 'Pacing Parson' plans another benefit walk across America
Auburn's man of sole isn't about to hang up his long-distance shoes. Don Stevenson is preparing this year to do a 3,000-mile walk across America – from Auburn to Silver Springs, Md. – to raise funds and awareness for pulmonary hypertension (PH), a high-blood pressure disease that affects the heart and lungs. The 79-year-old Stevenson hinted last year at retirement from cross country walks after completing a 20,000-mile trek to benefit the N…
Pregnancy in PAH Patients Focus of Recent Study
A recent systematic review titled “Pregnancy and pulmonary arterial hypertension: A clinical conundrum,” highlights that pulmonary arterial hypertension (PAH) is an absolute contraindication for pregnant women. Pulmonary arterial hypertension (PAH) is a rare condition that causes progressive increases in pulmonary arterial pressure and pulmonary vascular resistance, eventually leading to right ventricular failure and death. PAH affects mostly …
CTEPH Patients Are Better Assessed During and After Exercise
According to a recent study published in the journal Heart, RV afterload increases in patients with chronic thromboembolic pulmonary hypertension (CTEPH) during exercise, resulting in a marked reduction in RVEF and SV reserve. However, sildenafil may reverse this effect. In patients with pulmonary hypertension, RV function is the most relevant predictor of outcome, with studies with cardiac magnetic resonance (CMR) imaging showing the predicti…
Study Reviews Novel Molecular Target Advancements for the Treatment of Pulmonary Arterial Hypertension
A group of pulmonary medical specialists from the University of South Paris School of Medicine (USPSM) in France have conducted a robust review study that examines the increasing number of potential novel therapeutic drug targets for patients with pulmonary arterial hypertension (PAH). The study team, led by Dr. Marc Humbert, MD PhD, Professor of Respiratory Medicine, National Reference Centre for Pulmonary Hypertension at the Department of Resp…
Why do we still not have a cure for PH? And other research questions
In this issue of Research Corner, I will provide some insight into the challenges facing PH research, as well as answers to some of the questions posted on the PHA Canada Facebook page page. Why do we still not have a cure for PH? In order to be able to look at curing a disease, scientists have to know why/how the disease occurs and how it progresses, which requires understanding which systems, organs and cells are involved in the generation…
Ascendis to Start Phase 1 Study of PAH Treatment
Ascendis Pharma A/S is beginning its phase 1 single ascending dose study on healthy participants to evaluate a potential treatment for pulmonary arterial hypertension (PAH) called TransCon Treprostinil, as announced in a press release. The investigational therapy is one of a few promising drug candidates in the clinical stage biotechnology company’s portfolio, all of which use its novel TransCon technology to respond to the needs of patients who …
Arena Pharma Begins Dosing PAH Patients with Ralinepag in Phase II Study
San Diego, California-based biopharmaceutical company Arena Pharmaceuticals, Inc. just announced they have begun dosing patients in a Phase II clinical program for ralinepag, an orally available, non-prostanoid prostacyclin (IP) receptor agonist, formulated for the treatment of pulmonary arterial hypertension (PAH). Ralinepag has performed favorably in previous preclinical and clinical studies, and demonstrated a positive safety profile when d…
Could a National PH Registry Improve Research and Treatment in America? Russian Registry Shows Promise in New Study
Initial results are now available from a national registry that has been established in Russia to track individuals with pulmonary hypertension (PH), including chronic thromboembolic pulmonary hypertension (CTEPH). The research was published in Russian in the journal Terapevticheskii Arkhiv (translated to Therapeutic Archive). PH is a serious disease involving high blood pressure of the lungs due to capillary narrowing, which worsens over time…
Recent News

Subscribe

Get the latest on PH treatments, community events and more when you subscribe to our newsletter

ImagineCan_Accreditation_Trustmark_ENGFR_WHT-FNL_white.png